NCT01001754 - Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection | Biotech Hunter

Enrollment

600

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

May 31, 2012

Conditions

Hepatitis C, Chronic

Interventions

DRUG

PEG-rIL-29

Weekly SC injections in combination with ribavirin for up to 48 weeks

DRUG

Peginterferon alfa-2a

Weekly SC injections in combination with ribavirin for up to 48 weeks

DRUG

Ribavirin

Daily oral administration (400-600 mg BID)

Trial Locations (79)

10021

New York

11030

Manhasset

21093

Lutherville

22031

Fairfax

27710

Durham

28207

Charlotte

28677

Statesville

30308

Atlanta

32610

Gainesville

48202

Detroit

63104

St Louis

76012

Arlington

77030

Houston

78215

San Antonio

80045

Aurora

80113

Englewood

84132

Salt Lake City

87131

Albuquerque

92118

Coronado

92262

Palm Springs

94115

San Francisco

98101

Seattle

Unknown

Beverly Hills

La Jolla

Miami

Rochester

Newark

Philadelphia

Newport News

Herston

Adelaide

Camperdown

Clayton

Fitzroy

Fremantle

Greenslopes

Herston

Kogarah

Melbourne

Penrith

Perth

Westmead

Graz

Innsbruck

Linz

Vienna

Vancouver

London

Toronto

Paris

Pessac

Bochum

Cologne

Düsseldorf

Essen

Frankfurt am Main

Freiburg im Breisgau

Göttingen

Hamburg

Hanover

Heidelberg

Mainz

München

Tübingen

Milan

Bialystok

Krakow

Racibórz

Wroclaw

Łańcut

Santurce

Bucharest

Iași

Timișoara

Barcelona

Madrid

Majadahonda

Seville

Valencia